<p>全球阿爾法資本管理有限公司在最近提交給證券交易委員會的 13F 表格中披露，在第一季度將其在海默尼克斯公司的股份（紐約證券交易所代碼：HAE - 免費報告）增加了 61.1%。該公司在此期間額外購買了 10,452 股後，持有 27,553 股醫療儀器供應商的股票。全球阿爾法資本管理有限公司在最近一個季度末持有海默尼克斯約 0.05% 的股份，價值 1,751,000 美元。</p>
<p>其他機構投資者和對沖基金最近也增加或減少了在該公司的持股。路易斯安那州員工退休系統在第一季度將其在海默尼克斯的股份增加了 1.4%。路易斯安那州員工退休系統現在持有 14,100 股醫療儀器供應商的股票，價值 896,000 美元，此前在此期間額外購買了 200 股。CWC Advisors LLC 在第四季度將其在海默尼克斯的股份增加了 7.4%。CWC Advisors LLC 現在持有 3,083 股醫療儀器供應商的股票，價值 241,000 美元，此前在此期間額外購買了 212 股。Vise Technologies Inc.在第四季度將其在海默尼克斯的股份增加了 8.7%。Vise Technologies Inc.現在持有 2,825 股醫療儀器供應商的股票，價值 221,000 美元，此前在此期間額外購買了 225 股。TD Waterhouse Canada Inc.在第四季度購買了海默尼克斯的新股份，價值約 25,000 美元。最後，KBC Group NV 在第一季度將其在海默尼克斯的股份增加了 19.9%。KBC Group NV 現在持有 2,417 股醫療儀器供應商的股票，價值 154,000 美元，此前在此期間額外購買了 401 股。目前 99.67% 的股票由機構投資者持有。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾家研究公司最近對 HAE 發表了看法。摩根大通重申了對海默尼克斯的 “中性” 評級，並在週五的研究報告中將目標價下調至 62.00 美元（之前為 85.00 美元）。JMP 證券在 5 月 20 日的研究報告中重申了對海默尼克斯的 “市場表現優於大盤” 評級，並將目標價設定為 100.00 美元。Wall Street Zen 在 5 月 13 日的研究報告中將海默尼克斯的評級從 “買入” 下調至 “持有”。Needham &amp; Company LLC 在週四將海默尼克斯的目標價從 84.00 美元下調至 68.00 美元，並對該股票設定了 “買入” 評級。最後，瑞穗證券在週五將海默尼克斯的目標價從 90.00 美元下調至 70.00 美元，並對該股票設定了 “優於大盤” 評級。一位股票研究分析師對該股票給予了賣出評級，兩位給予了持有評級，八位給予了買入評級，兩位給予了強烈買入評級。根據 MarketBeat 的數據，該公司的共識評級為 “適度買入”，共識目標價為 87.64 美元。</p>
<p><strong>查看我們關於海默尼克斯的最新報告</strong></p>
<h2>海默尼克斯價格表現</h2>
<p>海默尼克斯的股票在週五開盤價為 53.88 美元。該公司的債務與股本比率為 1.04，速動比率為 0.99，流動比率為 1.72。該公司的市值為 25.9 億美元，市盈率為 16.48，市盈增長比率為 0.90，貝塔值為 0.40。該公司的 50 日移動平均線為 72.88 美元，200 日移動平均線為 67.44 美元。海默尼克斯公司的 52 周低點為 53.25 美元，52 周高點為 94.99 美元。</p>
<p>海默尼克斯（紐約證券交易所代碼：HAE - 獲取免費報告）最近在 8 月 7 日發佈了季度財報。該醫療儀器供應商報告季度每股收益為 1.10 美元，超出分析師一致預期的 1.01 美元，超出幅度為 0.09 美元。該公司季度收入為 3.2139 億美元，而分析師預期為 3.0512 億美元。海默尼克斯的股本回報率為 26.64%，淨利潤率為 12.14%。該公司的收入同比下降了 4.4%。在去年同期，該公司每股收益為 1.02 美元。股票研究分析師預測海默尼克斯公司本財年的每股收益將達到 4.55 美元。</p>
<h2>海默尼克斯簡介</h2>
<p>（免費報告）</p>
<p>海默尼克斯公司是一家醫療保健公司，在美國和國際上提供一系列醫療產品和解決方案。該公司提供自動化血漿採集系統、捐贈者管理軟件及支持軟件解決方案，包括 NexSys PCS 和 PCS2 血漿分離設備及相關耗材和解決方案，以及集成的信息技術平台，供血漿客户管理其捐贈者、運營和供應鏈；以及 NexLynk DMS 捐贈者管理系統和 Donor360 應用程序。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好五隻股票，而不是海默尼克斯</li>
<li>想在下跌趨勢中獲利？下跌趨勢解析。</li>
<li>MarketBeat 週迴顧 – 08/04 - 08/08</li>
<li>股票平均計算器</li>
<li>Airbnb 超出收益預期，但增長故事正在失去高度</li>
<li>股票中的死亡交叉是什麼？</li>
<li>Netflix 的多頭與空頭：誰將在這次回調中獲勝？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在海默尼克斯嗎？</h2>
<p>在你考慮海默尼克斯之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Haemonetics 並不在名單上。</p>
<p>雖然 Haemonetics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>全球阿爾法資本管理有限公司在第一季度將其在海蒙尼克斯公司（NYSE:HAE）的持股增加了 61.1%，增持了 10,452 股，總持股達到 27,553 股，價值 175 萬美元。其他機構投資者也調整了他們的持股。分析師對海蒙尼克斯的評級意見不一，普遍評級為 “適度買入”，目標價為 87.64 美元。該股票開盤價為 53.88 美元，市值為 25.9 億美元，最近的每股收益為 1.10 美元，超出預期。海蒙尼克斯報告的收入同比下降了 4.4%</p>

<p>Global Alpha Capital Management Ltd. boosted its position in shares of Haemonetics Corporation (NYSE:HAE - Free Report) by 61.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm owned 27,553 shares of the medical instruments supplier's stock after acquiring an additional 10,452 shares during the period. Global Alpha Capital Management Ltd. owned approximately 0.05% of Haemonetics worth $1,751,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>全球阿爾法資本管理有限公司在最近提交給證券交易委員會的 13F 表格中披露，在第一季度將其在海默尼克斯公司的股份（紐約證券交易所代碼：HAE - 免費報告）增加了 61.1%。該公司在此期間額外購買了 10,452 股後，持有 27,553 股醫療儀器供應商的股票。全球阿爾法資本管理有限公司在最近一個季度末持有海默尼克斯約 0.05% 的股份，價值 1,751,000 美元。</p>
</div><p>Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System grew its stake in shares of Haemonetics by 1.4% in the 1st quarter. Louisiana State Employees Retirement System now owns 14,100 shares of the medical instruments supplier's stock valued at $896,000 after purchasing an additional 200 shares during the period. CWC Advisors LLC. grew its stake in shares of Haemonetics by 7.4% in the 4th quarter. CWC Advisors LLC. now owns 3,083 shares of the medical instruments supplier's stock valued at $241,000 after purchasing an additional 212 shares during the period. Vise Technologies Inc. grew its stake in shares of Haemonetics by 8.7% in the 4th quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier's stock valued at $221,000 after purchasing an additional 225 shares during the period. TD Waterhouse Canada Inc. bought a new stake in shares of Haemonetics in the 4th quarter valued at approximately $25,000. Finally, KBC Group NV grew its stake in shares of Haemonetics by 19.9% in the 1st quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier's stock valued at $154,000 after purchasing an additional 401 shares during the period. 99.67% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他機構投資者和對沖基金最近也增加或減少了在該公司的持股。路易斯安那州員工退休系統在第一季度將其在海默尼克斯的股份增加了 1.4%。路易斯安那州員工退休系統現在持有 14,100 股醫療儀器供應商的股票，價值 896,000 美元，此前在此期間額外購買了 200 股。CWC Advisors LLC 在第四季度將其在海默尼克斯的股份增加了 7.4%。CWC Advisors LLC 現在持有 3,083 股醫療儀器供應商的股票，價值 241,000 美元，此前在此期間額外購買了 212 股。Vise Technologies Inc.在第四季度將其在海默尼克斯的股份增加了 8.7%。Vise Technologies Inc.現在持有 2,825 股醫療儀器供應商的股票，價值 221,000 美元，此前在此期間額外購買了 225 股。TD Waterhouse Canada Inc.在第四季度購買了海默尼克斯的新股份，價值約 25,000 美元。最後，KBC Group NV 在第一季度將其在海默尼克斯的股份增加了 19.9%。KBC Group NV 現在持有 2,417 股醫療儀器供應商的股票，價值 154,000 美元，此前在此期間額外購買了 401 股。目前 99.67% 的股票由機構投資者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several research firms have recently weighed in on HAE. JPMorgan Chase &amp; Co. reiterated a &#34;neutral&#34; rating and issued a $62.00 price objective (down from $85.00) on shares of Haemonetics in a research note on Friday. JMP Securities reiterated a &#34;market outperform&#34; rating and issued a $100.00 price objective on shares of Haemonetics in a research note on Tuesday, May 20th. Wall Street Zen lowered Haemonetics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, May 13th. Needham &amp; Company LLC lowered their price objective on Haemonetics from $84.00 to $68.00 and set a &#34;buy&#34; rating on the stock in a research note on Thursday. Finally, Mizuho lowered their price objective on Haemonetics from $90.00 to $70.00 and set an &#34;outperform&#34; rating on the stock in a research note on Friday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $87.64.</p>
<div class="lb-trans"><p>幾家研究公司最近對 HAE 發表了看法。摩根大通重申了對海默尼克斯的 “中性” 評級，並在週五的研究報告中將目標價下調至 62.00 美元（之前為 85.00 美元）。JMP 證券在 5 月 20 日的研究報告中重申了對海默尼克斯的 “市場表現優於大盤” 評級，並將目標價設定為 100.00 美元。Wall Street Zen 在 5 月 13 日的研究報告中將海默尼克斯的評級從 “買入” 下調至 “持有”。Needham &amp; Company LLC 在週四將海默尼克斯的目標價從 84.00 美元下調至 68.00 美元，並對該股票設定了 “買入” 評級。最後，瑞穗證券在週五將海默尼克斯的目標價從 90.00 美元下調至 70.00 美元，並對該股票設定了 “優於大盤” 評級。一位股票研究分析師對該股票給予了賣出評級，兩位給予了持有評級，八位給予了買入評級，兩位給予了強烈買入評級。根據 MarketBeat 的數據，該公司的共識評級為 “適度買入”，共識目標價為 87.64 美元。</p>
</div><p><strong>Check Out Our Latest Report on Haemonetics</strong></p>
<div class="lb-trans"><p><strong>查看我們關於海默尼克斯的最新報告</strong></p>
</div><h2>Haemonetics Price Performance</h2>
<div class="lb-trans"><h2>海默尼克斯價格表現</h2>
</div><p>Haemonetics stock opened at $53.88 on Friday. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.99 and a current ratio of 1.72. The firm has a market cap of $2.59 billion, a P/E ratio of 16.48, a P/E/G ratio of 0.90 and a beta of 0.40. The business's fifty day moving average is $72.88 and its two-hundred day moving average is $67.44. Haemonetics Corporation has a 52 week low of $53.25 and a 52 week high of $94.99.</p>
<div class="lb-trans"><p>海默尼克斯的股票在週五開盤價為 53.88 美元。該公司的債務與股本比率為 1.04，速動比率為 0.99，流動比率為 1.72。該公司的市值為 25.9 億美元，市盈率為 16.48，市盈增長比率為 0.90，貝塔值為 0.40。該公司的 50 日移動平均線為 72.88 美元，200 日移動平均線為 67.44 美元。海默尼克斯公司的 52 周低點為 53.25 美元，52 周高點為 94.99 美元。</p>
</div><p>Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 EPS for the quarter, topping analysts' consensus estimates of $1.01 by $0.09. The company had revenue of $321.39 million for the quarter, compared to analyst estimates of $305.12 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%. The business's revenue was down 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.02 earnings per share. Equities research analysts forecast that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>海默尼克斯（紐約證券交易所代碼：HAE - 獲取免費報告）最近在 8 月 7 日發佈了季度財報。該醫療儀器供應商報告季度每股收益為 1.10 美元，超出分析師一致預期的 1.01 美元，超出幅度為 0.09 美元。該公司季度收入為 3.2139 億美元，而分析師預期為 3.0512 億美元。海默尼克斯的股本回報率為 26.64%，淨利潤率為 12.14%。該公司的收入同比下降了 4.4%。在去年同期，該公司每股收益為 1.02 美元。股票研究分析師預測海默尼克斯公司本財年的每股收益將達到 4.55 美元。</p>
</div><h2>Haemonetics Profile</h2>
<div class="lb-trans"><h2>海默尼克斯簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.</p>
<div class="lb-trans"><p>海默尼克斯公司是一家醫療保健公司，在美國和國際上提供一系列醫療產品和解決方案。該公司提供自動化血漿採集系統、捐贈者管理軟件及支持軟件解決方案，包括 NexSys PCS 和 PCS2 血漿分離設備及相關耗材和解決方案，以及集成的信息技術平台，供血漿客户管理其捐贈者、運營和供應鏈；以及 NexLynk DMS 捐贈者管理系統和 Donor360 應用程序。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Haemonetics</li>
<li>Want to Profit on the Downtrend? Downtrends, Explained.</li>
<li>MarketBeat Week in Review – 08/04 - 08/08</li>
<li>Stock Average Calculator</li>
<li>Airbnb Beats Earnings, But the Growth Story Is Losing Altitude</li>
<li>What is a Death Cross in Stocks?</li>
<li>Netflix Bulls vs. Bears: Who Wins This Pullback?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好五隻股票，而不是海默尼克斯</li>
<li>想在下跌趨勢中獲利？下跌趨勢解析。</li>
<li>MarketBeat 週迴顧 – 08/04 - 08/08</li>
<li>股票平均計算器</li>
<li>Airbnb 超出收益預期，但增長故事正在失去高度</li>
<li>股票中的死亡交叉是什麼？</li>
<li>Netflix 的多頭與空頭：誰將在這次回調中獲勝？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=HAE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Haemonetics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在海默尼克斯嗎？</h2>
</div><p>Before you consider Haemonetics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮海默尼克斯之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Haemonetics 並不在名單上。</p>
</div><p>While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Haemonetics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Global Alpha Capital Management Ltd. 購入了海蒙尼蒂克公司（NYSE: HAE）10,452 股股票